Significant acceptances by SCHWARZ shareholders for UCB tender offer

13-Dec-2006

The final total of acceptances received by midnight on Friday December 8 will be available on Thursday December 14, 2006. Acceptances already counted show UCB has received tenders in excess of 76% of the fully diluted share capital of SCHWARZ PHARMA. As is required in such a transaction in Germany, the offer will be extended for an additional two weeks.

Roch Doliveux, CEO of UCB, said, "I am delighted with the results of the tender offer so far. The current level of acceptances already received from SCHWARZ shareholders will allow the two companies to capture significant benefits of this exciting business combination, on which our resources will be focused. I thank shareholders for their support in building UCB as the next generation biopharmaceutical leader."

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance